Abstract
It has been found earlier that the bradykinin antagonist, icatibant (Hoe 140), prevents the pancreatic oedema and the ensuing hypotension and haemoconcentration, and facilitates the removal of activated enzymes from the tissue during caerulein-induced acute pancreatitis. For a potential therapeutic use of the compound in clinical situations it is essential to investigate whether the associated increase in enzyme activities in the blood serum has any adverse effects on the pancreas itself or on other organs.
Normal amylase secretion into the biliopancreatic duct stimulated by a low dose of caerulein (0.4 nmol kg−1 h−1, i.v.) was not affected by icatibant (100 nmolkg−1, s.c.). Acute pancreatitis, induced by a high dose of caerulein (4 nmol kg−1 h−1 for 2 h, i.v.), resulted in elevations in the activities of amylase and lipase in the pancreatic tissue and in the blood serum lasting for at least 4 h after the end of the caerulein infusion. While the rise in enzyme activities in the blood serum was augmented in icatibant-treated rats only at the end of the caerulein-infusion, the enzyme accumulation in the pancreas was significantly reduced by icatibant for at least 4 h after the end of the caerulein infusion. The secretion of amylase and lipase into the biliopancreatic duct was significantly increased only during the first 20 min of acute pancreatitis; in rats pre-treated with icatibant, no significant increase could be observed. Twenty-four hours after induction of pancreatitis, a low-dose caerulein stimulation of the exocrine function of the pancreas led to a reduced but sustained secretion of amylase regardless of whether the animals had received icatibant or not. During the first 45 min of pancreatitis, blood glucose concentrations were significantly reduced, but returned to values not different from those obtained in saline-infused controls. This effect was not affected by icatibant. No changes in the response to an i.v. glucose tolerance test were found on the day after induction of acute pancreatitis. The serum activities of glutamic pyruvic transaminase and γ-glutamyl transpeptidase determined up to 24 h after induction of pancreatitis were not different from saline controls. Icatibant had no effect on the activities of these enzymes.
It is concluded that during caerulein-induced acute pancreatitis normal exocrine secretion of pancreatic enzymes into the pancreatic duct ceases almost immediately. Pre-treatment with icatibant significantly reduces the accumulation of activated enzymes in the pancreatic tissue for several hours after induction of pancreatitis while a concomitant augmentation in enzyme activities in the blood serum lasts much shorter. There is no indication of adverse effects on the function of the endocrine or exocrine pancreas and that of the liver, either during the acute stages of pancreatitis or during the recovery period.
Similar content being viewed by others
References
Adler G, Hupp T, Kern HF (1979) Course and spontaneous regression of acute pancreatitis in the rat. Virchows Arch [A] 382:31–47
Adler G, Rohr G, Kern HF (1982) Alterations of membrane fusion as a cause of acute pancreatitis. Dig Dis Sci 27:993–1002
Bhoola KD, Lemon M, Matthews R (1979) Kallikrein in exocrine glands. In: Erdös EG (ed) Bradykinin, kallidin and kallikrein (Handbook of Experimental Pharmacology, vol 25, Supplement). Springer, Berlin Heidelberg New York, pp 489–523
Bloechle C, Kühn R, Knoefel WT, Yekebas E, Kusterer K, Izbicki JR (1995) Bradykinin-antagonist Hoe 140 prevents microcirculatory stasis and tissue necrosis in taurocholate induced pancreatitis in the rat. Pancreas 9:783
Bilchler M (1991) Objectification of the severity of acute pancreatitis. Hepatogastroenterology 38:101–108
Conover WJ (1980) Practical nonparametric statistics, 2nd edn. Wiley, New York
Creutzfeldt W, Schmidt H (1970) Aetiology and pathogenesis of pancreatitis. Scand J Gastroenterol 5 [Suppl 6]:47–62
Egdahl RH (1958) Mechanism of blood enzyme changes following the production of experimental pancreatitis. Ann Surg 148:389–399
Elsasser HP, Adler G, Kern HF (1989) Fibroblast structure and function during regeneration from hormone-induced acute pancreatitis in the rat. Pancreas 4:169–178
Fernandez del Castillo C, Schmidt J, Warshaw AL, Rattner DW (1994) Interstitial protease activation is the central event in progression to necrotizing pancreatitis. Surgery 116:497–504
Gress TM, Arnold R, Adler G (1990) Structural alterations of pancreatic microvasculature in caerulein-induced pancreatitis in the rat. Res Exp Med (Berl) 190:401–412
Griesbacher T, Lembeck F (1992) Effects of the bradykinin antagonist, HOE 140, in experimental acute pancreatitis. Br J Pharmacol 107:356–360
Griesbacher T, Tiran B, Lembeck F (1993a) Pathological events in experimental acute pancreatitis prevented by the bradykinin antagonist, HOE 140. Br J Pharmacol 108:405–411
Griesbacher T, Lembeck F, Kolbitsch C, Titan B (1993b) Fate of pancreatic enzymes in caerulein-induced acute pancreatitis and effects of the bradykinin antagonist, HOE 140. Br J Pharmacol 108:58P
Hock FJ, Wirth K, Albus U, Linz W, Gerhards HJ, Wiemer G, Henke S, Breipohl G, König W, Knolle J, Schölkens BA (1991) Hoe 140, a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 102:769–773
Howard JM, Smith AK, Peters JJ (1949) Acute pancreatitis: pathways of enzymes into the blood stream. Surgery 26:161–166
Karlsson S, Ahrén B (1991) CCKA receptor antagonism inhibits mechanisms underlying CCK-8-stimulated insulin release in isolated rats islets. Eur J Pharmacol 202:253–257
Kraut H, Frey EK, Werle E (1930) Der Nachweis eines Kreislaufhormons in der Pankreasdrüse. Hoppe-Seylers Z Physiol Chem 189:97–102
Lampel M, Kern H (1977) Acute interstitial pancreatitis in the rat induced by excessive doses of pancreatic secretagogue. Virchows Arch [A] 373:97–117
Lembeck F, Griesbacher T, Eckhardt M, Henke S, Breipohl G, Knolle J (1991) New, long-acting, potent bradykinin antagonists. Br J Pharmacol 102:297–304
McEntee G, Kelly D (1991) The microvasculature in acute pancreatitis. In: Johnson CD, Imrie CW (eds) Pancreatic disease: progress and prospects. Springer, London Berlin Heidelberg, pp 251–260
Pitchumoni CS, Agarwal N, Jain NK (1988) Systemic complications of acute pancreatitis. Am J Gastroenterol 83:597–606
Saluja A, Hashimoto S, Saluja M, Powers RE, Meldolesi J, Steer ML (1987) Subcellular redistribution of lysosomal enzymes during caerulein-induced pancreatitis. Am J Physiol 253:G508-G516
San Román JI, de Dios I, Manso MA, Calvo JJ, López MA (1990) Caerulein-induced acute pancreatitis in the rat. Pancreatic secretory response to cholecystokinin. Arch Int Physiol Biochim Biophys 98:237–243
Watanabe O, Baccino FM, Steer ML, Meldolesi J (1984) Supramaximal stimulation and ultrastructure of rat pancreatic acinar cell: early morphological changes during development of experimental pancreatitis. Am J Physiol 246:G457-G467
Weaver FC, Sorenson RL (1989) Islet vasculature in atrophic pancreas: evidence for co-existing parallel and serial (insuloacinar) angioarchitecure. Pancreas 4:10–22
Werle E (1960) Kallikrein, kallidin, and related substances. In: Schachter M (ed) Polypeptides which affect smooth muscles and blood vessels. Pergamon, Oxford, pp 199–209
Werle E, Tauber K, Hartenbach W, Forrell MM (1958) Zur Frage der Therapie der Pankreatitis. Münch Med Wochenschr 100:1265–1267
Willemer S, Adler G (1989) Histochemical and ultrastructural characteristics of tubular complexes in human acute pancreatitis. Dig Dis Sci 34:46–55
Willemer S, Elsasser HP, Kern HF, Adler G (1987) Tubular complexes in cerulein- and oleic acid-induced pancreatitis in rats: glycoconjugate pattern, immunocytochemical, and ultrastructural findings. Pancreas 2:669–675
Willemer S, Klöppel G, Kern HF, Adler G (1989) Immunocytochemical and morphometric analysis of acinar zymogen granules in human acute pancreatitis. Virchows Arch [A] 415: 115–123
Willemer S, Bialek R, Köhler H, Adler G (1990) Caerulein-induced acute pancreatitis in rats: changes in glycoprotein-composition of subcellular membrane systems in acinar cells. Histochemistry 95:87–96
Wirth K, Hock FJ, Albus U, Linz W, Alpermann HG, Anagnostopoulos H, Henke S, Breipohl G, König W, Knolle J, Schölkens BA (1991) Hoe 140, a new potent and long acting bradykinin antagonist: in vivo studies. Br J Pharmacol 102:774–777
Zar JH (1984) Biostatistical Analysis, 2nd edn. Prentice Hall, Englewood Cliffs, pp 199–201
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Griesbacher, T., Kolbitsch, C., Tiran, B. et al. Effects of the bradykinin antagonist, icatibant (Hoe 140), on pancreas and liver functions during and after caerulein-induced pancreatitis in rats. Naunyn-Schmiedeberg's Arch Pharmacol 352, 557–564 (1995). https://doi.org/10.1007/BF00169391
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00169391